Advanced search
Publication Cover
HIV Clinical Trials Volume 2, 2001 - Issue 5
Submit an article Journal homepage
49
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Study Protocol for the Evaluation of the Potential for Durable Viral Suppression After Quadruple HAART With or Without HIV Vaccination: The QUEST Study

Li-Ean GohDepartment of HIV & Opportunistic InfectionsGlaxoSmithKline, Research and Development, GlaxoSmithKline, Greenford Road, Greenford, Middlesex, United Kingdom.
,
Luc PerrinHôpital CantonalDépartement de Médecine Interne, Division des Maladies Infectieuses, Laboratoire Central de Virologie, Geneva, Switzerland
,
Bruno HoenUniversite de Franche-Comte, Department of Infectious Diseases, University Medical Centre, Besancon, France
,
David CooperNational Centre in HIV Epidemiology and Clinical ResearchUniversity of New South Wales, Sydney, Australia
,
Andrew PhillipsThe Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom
,
George JanossyHIV Immunology UnitDepartment of Immunology, Royal Free and University College Medical School, The Royal Free Campus, London, United Kingdom
,
Anders SonnenborgDepartment of Infectious DiseasesHuddinge University Hospital, Huddinge, Sweden
,
Chris TsoukasMontreal General HospitalImmune Deficiency Treatment Centre, Montreal, Quebec, Canada
,
Fiona LampeThe Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom
,
Sabine KinlochHIV Immunology UnitDepartment of Immunology, Royal Free and University College Medical School, The Royal Free Campus, London, United Kingdom
& on behalf of the QUEST Study Group show all
Pages 438-444 | Published online: 02 Feb 2015

REFERENCES

  • Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
  • Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123–126.
  • Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605–1613.
  • Monforte AA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive subjects. AIDS. 2000;14:499–507.
  • Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–87.
  • Brinkman K, Smeitink, JA, Romijin JA, Reiss P. Mitochon-drial toxicity induced by nucleoside-analogue reverse tran-scriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy related lipodystrophy. Lancet. 1999;354:1112–1115.
  • Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-specific CD4+ T cell responses associated with con-trol of viremia. Science. 1997;278:1447–1450.
  • Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected subjects receiving highly active antiretroviral therapy. Nat Med. 1999;6:651–655.
  • Goh LE, McDade H, Kinloch S, et al. The QUEST trial, a paradigm of HIV collaborative research. Nat Med. 2000;6:1194.
  • Clinical Investigator's Brochure, ALVAC(2) 120 (B, MN)GNP (vCP1452). Pennsylvania: Aventis Pasteur Inc.; 1999.
  • Churdboonchart V, Sakondhavat C, Kulpradist S, et al. A double blind, adjuvant-controlled trial of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen (REMUNE) monotherapy in asymptomatic, HIV-1-infected Thai sub-jects with CD4-cell counts of >300. Clin Diag Lab ImmunoL 2000;7:728–733.
  • Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provide a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512–517.
  • Chun T, Fauci A. Latent reservoirs of HIV: Obstacles to the eradication of virus. Proc Nat/ Acad Sci USA. 1999;96;10958–10961.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.